About the AG

  • Subscribe to the AG's RSS Feed
  • Join the AG's FaceBook
  • Follow the AG on Twitter
  • View the AG's YouTube Channel
  • View the AG's Tumblr Page

Annual Progress Report Requirement

The Panel Office is required to monitor all current ongoing Schedule I and Schedule II controlled substance research activity in California.

In order to accomplish this, the Panel requires an annual Progress Report from each Sponsor/CRO - not from individual California site - and PI, whose research was approved between September and August of the previous year to be forwarded to the Panel office in PDF format via e-mail (No hard copy required) by February 25th every year. For example, for the 2014 Annual Progress Report, the researches approved between September 2013 and August 2014 need to be sent by February 25, 2015. The Panel will send out an e-mail reminder to the Sponsor/CRO/PI at the end of January every year.

There is no particular format required, however, the report should include:

  1. A brief summary of research performed and findings made during the calendar year (this requirement may be augmented by including reprints of papers or copies of reports published)
  2. Research plans for the upcoming calendar year (with indication of any additional controlled substances planned for procurement in the upcoming year)
  3. Notation of any changes in the research project, (substantive changes should be explained in detail so that the Panel can review them as protocol amendments), and
  4. A photocopy of the controlled substances inventory log maintained at you site for record keeping (if applicable).

Since reporting an annual progress report to the Panel is a mandatory requirement, the Panel Office does not send an acknowledge letter to each Sponsor/CRO/PI.

The Panel also requires notification of completion, and a final report including a completion date, to be forwarded to the Panel office via PDF format when each study is completed.

Site Navigation

Translate Website

  • Google™ Translation Disclaimer

This Google™ translation feature is provided for informational purposes only.

The Office of the Attorney General is unable to guarantee the accuracy of this translation and is therefore not liable for any inaccurate information resulting from the translation application tool.

Please consult with a translator for accuracy if you are relying on the translation or are using this site for official business.

If you have any questions please contact:Bilingual Services Program at (916) 324-5482

A copy of this disclaimer can also be found on our Disclaimer page.

Select a Language Below / Seleccione el Idioma Abajo

Close this box or use the [ X ]